Vivos Therapeutics, Inc. VVOS 深 滬
等待開盤 09-10 09:30:00 美东时间
3.865
+0.035
+0.91%
華盛通- 最 高4.02
- 今 開3.83
- 成交量 6.16万股
- 最 低 3.8109
- 昨 收 3.83
- 總市值 2276.29万
- 52周最高 7.95
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.98
- 委 比 23.46%
- 總股本 588.95万
- 歷史最高 360.25
- 量 比 0.59
- 振 幅 5.46%
- 歷史最低 1.91
- 每 手 1
- 風險率 4.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
40分钟前
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.5
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $6.2 to $6.5.
09-09 19:18
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) shares rose 34.6% to $0.7 during Friday's a...
08-23 05:07
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
08-20 04:23
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. will release its Q2 2025 financial results after market close on August 19, 2025, followed by a conference call at 5:00 pm ET to discuss results and recent developments. The call can be accessed by dialing (800) 717-1738 (US) or (646) 307-1865 (int'l), with a replay available until September 2, 2025. A live webcast and archive will be available on Vivos' website. The company focuses on treating sleep-related breathing dis...
08-19 12:30
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
<p>Vivos Therapeutics, Inc. (NASDAQ: VVOS) 宣布两项关键任命——Michael Bruhn 担任执行副总裁，负责业务整合运营，以及 Dr. Terry Jones 任高级副总裁，负责人力资源，以支持其在睡眠测试中心和患者治疗服务方面的扩展。Bruhn 将推动公司在东海岸的业务扩展及新收购的整合，而 Jones 则将加强公司的人力资源管理。两人的加入体现了 Vivos 在新业务模式下快速增长的承诺。Vivos 目前正在积极寻求类似收购以提升收入。</p>
07-30 12:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Vivos Therapeutics' FDA-cleared VidaSleep™ oral appliance has been approved by CMS for treating mild to moderate obstructive sleep apnea (OSA) and snoring, benefiting millions of Medicare beneficiaries. With over 80% of U.S. OSA cases undiagnosed, Vivos' dual-PDAC approval positions it as the only company with two Medicare-covered oral appliances, addressing a significant portion of the $36 billion sleep therapy market. The VidaSleep™ device, fea...
07-01 12:30
Vivos Therapeutics Announces European Journal Of Pediatrics Publishes Results Of Multicenter Clinical Trial Results For Treatment Of OSA In Children Using Vivos' Patented Daytime-Nighttime Appliance
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published
06-26 20:32
